|
|
 |
|
Viewing report
|
|
|
|
Breast Cancer - Changing Treatment Paradigms For Local And Locally Advanced Breast Cancer
Datamonitor, April 2005, Pages: 199
Anthracycline-based regimens and tamoxifen are well-established in the treatment of early-stage breast cancer. In recent days, however, agents such as Sanofi-Aventiss Taxotere and AstraZenecas Arimidex have been gaining prominence. This report examines the current treatment paradigms for early-stage breast cancer, based on primary research data from 180 physicians in the seven major markets.
Report Scope:
- Analysis of current treatment practices for early-stage breast cancer based on primary research from 180 physicians in the seven major markets
- Extent of use of antihormonal agents, such as anti-estrogens and aromatase inhibitors, in local and locally-advanced breast cancer
- Physician awareness and ratings of late-stage pipeline drugs for breast cancer, including recently launched APPs Abraxane and GSKs lapatinib
- Coverage of adjuvant and neoadjuvant chemotherapy in early-stage breast cancer, including the commonly used regimens in each setting
Report Highlights:
Sanofi-Aventiss Taxotere (docetaxel) is likely to see a significant increase in its use as adjuvant and neoadjuvant therapies in combination with anthracycline-based regimens. However, Sanofi-Aventis will need to disseminate relevant trial results to physicians to compete with the likes of paclitaxel, especially in the US.
AstraZenecas Arimidex (anastrozole) will replace tamoxifen as the gold-standard adjuvant therapy for local and locally advanced breast cancer, given the latest ATAC trial results in December 2004.
Abraxane (albumin-bound paclitaxel) had the highest awareness rate among late-stage pipeline drugs, as well as being considered the most promising agent. Its recent launch and potential success in metastatic disease is likely to be translated into the adjuvant and neoadjuvant settings.
Reasons to Purchase:
- Identify the key chemotherapy regimens in the neoadjuvant and adjuvant settings for local and locally-advanced breast cancer
- Target physicians effectively through an understanding of prescribing behavior for antihormonal agents in pre- and postmenopausal breast cancer
- Evaluate product potential by assessing physician awareness and rating of key late-stage pipeline drugs for breast cancer
Customers who bought this item also bought
Pipeline Insight: Breast Cancer - Recent Approvals Increase Pressure On Pipeline Candidates
U.S. Breast Cancer Therapeutics Markets
Pipeline Insight: Breast Cancer - A Diverse & Increasingly Crowded Pipeline
Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor types
Breast Cancer - Therapeutic And Competitive Insights
Lynn Sage Breast Cancer Symposium
Triple Analysis: The Drug Target Atlas of Apoptopic Drugs in Oncology and Special Focus on Breast and Prostate Cancer
Breast Cancer Drug Discoveries: What the Future Holds
Breast Cancer Therapeutics - Global Strategic Business Report
Stakeholder Insight: Breast Cancer Chemotherapy
Analytical Tool - Breast Cancer
Chinese Markets for Breast Cancer Treatment Drugs
|
|
|
|
